An interventional study of Preoperative MRI in Pancreatic Cancer, Pancreatic Neoplasm and Liver Metastases, sponsored by University of Aarhus. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by University of Aarhus · Not applicable, Interventional, and Diagnostic
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's planned enrollment of 200 is above the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
MRI before surgery.
Diagnostic Test: Preoperative MRI
Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
Change in treatment strategy
Change in treatment strategy from intended curative resection to other treatment based on MRI scan
Time frame: 1 week
Liver metastases
Proportion of patients who had liver metastases detected on MRI
Time frame: 1 week
Surgery
Proportion of patients who made it to surgery/exploration
Time frame: 1 month
Resection
Proportion of patients in each arm who had a pancreatic resection performed
Time frame: 1 month
Intraoperatively detected liver metastases
Proportion of patients with intraoperatively detected liver metastases not seen on either CT or MRI.
Time frame: 1 month
Overall survival (1-year)
1-year overall survival.
Time frame: 1 year
Overall survival (3-year)
3-year overall survival.
Time frame: 3 years
Recurrence-free survival
Recurrence-free survival according to final treatment strategy.
Time frame: 3 years
Healthcare costs
Healthcare costs in patients with change of treatment.
Time frame: 3 years
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — Due to Danish law, no individual-level data can be shared.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus